- Home
- Publications
- Publication Search
- Publication Details
Title
Cilostazol for treatment of cerebral infarction
Authors
Keywords
-
Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume -, Issue -, Pages 1-8
Publisher
Informa UK Limited
Online
2018-09-14
DOI
10.1080/14656566.2018.1515199
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cilostazol Attenuates Angiotensin II–Induced Abdominal Aortic Aneurysms but Not Atherosclerosis in Apolipoprotein E–Deficient MiceHighlights
- (2018) Ryoko Umebayashi et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Heart Disease and Stroke Statistics—2018 Update: A Report From the American Heart Association
- (2018) Emelia J. Benjamin et al. CIRCULATION
- Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer’s disease
- (2017) Jos Prickaerts et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Cilostazol reduces blood brain barrier dysfunction, white matter lesion formation and motor deficits following chronic cerebral hypoperfusion
- (2016) Hamidreza Edrissi et al. BRAIN RESEARCH
- 2016 European Guidelines on cardiovascular disease prevention in clinical practice
- (2016) Massimo F. Piepoli et al. EUROPEAN HEART JOURNAL
- Cilostazol ameliorates collagenase-induced cerebral hemorrhage by protecting the blood–brain barrier
- (2016) Toshinori Takagi et al. JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
- Antiplatelet Agents for the Secondary Prevention of Ischemic Stroke or Transient Ischemic Attack: A Network Meta-Analysis
- (2016) Wen Wang et al. Journal of Stroke & Cerebrovascular Diseases
- Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis
- (2016) Peng-Peng Niu et al. BMJ Open
- Antiplatelet Agents for the Secondary Prevention of Ischemic Stroke or Transient Ischemic Attack: A Network Meta-Analysis
- (2016) Wen Wang et al. Journal of Stroke & Cerebrovascular Diseases
- Secondary Stroke Prevention: From Guidelines to Clinical Practice
- (2016) Glenn D. Graham JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION
- Neuroprotective effects of cilostazol are mediated by multiple mechanisms in a mouse model of permanent focal ischemia
- (2015) Hideo Shichinohe et al. BRAIN RESEARCH
- Efficacy and Safety of Cilostazol Therapy in Ischemic Stroke: A Meta-analysis
- (2015) Liang Tan et al. Journal of Stroke & Cerebrovascular Diseases
- Characterization of White Matter Injury in a Rat Model of Chronic Cerebral Hypoperfusion
- (2015) Bo-Ryoung Choi et al. STROKE
- Long‐Term Antiplatelet Mono‐ and Dual Therapies After Ischemic Stroke or Transient Ischemic Attack: Network Meta‐Analysis
- (2015) Wuxiang Xie et al. Journal of the American Heart Association
- Efficacy and Safety of Cilostazol Therapy in Ischemic Stroke: A Meta-analysis
- (2015) Liang Tan et al. Journal of Stroke & Cerebrovascular Diseases
- The efficacy and safety of cilostazol for the secondary prevention of ischemic stroke in acute and chronic phases in Asian population- an updated meta-analysis
- (2014) LiGen Shi et al. BMC Neurology
- Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): A Randomized, Open-Label, Parallel-Group Trial
- (2014) Kazunori Toyoda et al. International Journal of Stroke
- Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
- (2014) Walter N. Kernan et al. STROKE
- Anderson-Fabry Disease: A Multiorgan Disease
- (2013) Antonino Tuttolomondo et al. CURRENT PHARMACEUTICAL DESIGN
- Neurological Complications of Anderson-Fabry Disease
- (2013) Antonino Tuttolomondo et al. CURRENT PHARMACEUTICAL DESIGN
- Global and regional burden of stroke during 1990–2010: findings from the Global Burden of Disease Study 2010
- (2013) Valery L Feigin et al. LANCET
- An Updated Definition of Stroke for the 21st Century
- (2013) Ralph L. Sacco et al. STROKE
- Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010
- (2012) Christopher J L Murray et al. LANCET
- Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010
- (2012) Rafael Lozano et al. LANCET
- Cilostazol Inhibits Accumulation of Triglyceride in Aorta and Platelet Aggregation in Cholesterol-Fed Rabbits
- (2012) Hideki Ito et al. PLoS One
- Anti-platelet therapy: phosphodiesterase inhibitors
- (2011) Paolo Gresele et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Cilostazol in patients with ischemic stroke
- (2011) Zaid A Al-Qudah et al. EXPERT OPINION ON PHARMACOTHERAPY
- Protective Effects of Cilostazol against Transient Focal Cerebral Ischemia and Hemorrhagic Transformation
- (2011) Mitsunori ISHIGURO et al. YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN
- Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial
- (2010) Yukito Shinohara et al. LANCET NEUROLOGY
- Influence of CYP3A and CYP2C19 Genetic Polymorphisms on the Pharmacokinetics of Cilostazol in Healthy Subjects
- (2009) H-D Yoo et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Evaluation of the Antiplatelet Effects of Cilostazol, a Phosphodiesterase 3 Inhibitor, by VASP Phosphorylation and Platelet Aggregation
- (2008) Hiromi Yamamoto et al. CIRCULATION JOURNAL
- Cilostazol and peripheral arterial disease
- (2008) Lyndsay Pearce et al. EXPERT OPINION ON PHARMACOTHERAPY
- Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study
- (2008) Yining Huang et al. LANCET NEUROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started